利索-全球专利检索

  1. 登录
  2. 注册

搜索结果

29 条记录 (耗时 0.035 秒)

    Method for determining differences in molecular interactions and for screening a combinatorial library
    4.
    发明授权
    Method for determining differences in molecular interactions and for screening a combinatorial library 失效
    确定分子相互作用差异和筛选组合文库的方法

    公开(公告)号：US07291456B2

    公开(公告)日：2007-11-06

    申请号：US10057178

    申请日：2002-01-24

    申请人： Kit S. Lam ,  Alan L. Lehman

    发明人： Kit S. Lam ,  Alan L. Lehman

    IPC分类号： C12Q1/68

    CPC分类号： G01N33/543

    摘要： The invention includes a method for determining the differences between the molecular interactions of two different mixtures of molecules and identifying ligands specific for molecules in one mixture. The method utilizes a combinatorial library to compare the molecular interactions of the two mixtures and eliminates those interactions that are common to both mixtures and those that are unique to the first mixture, such that interactions essentially unique to the target mixture are identified. Ligands specific for molecules in the target mixture can then be identified. The invention also includes a method of screening a combinatorial library to distinguish between true positive beads and false positive beads and to provide for the identification of ligands specific for target molecules.

    摘要翻译： 本发明包括用于确定两种不同分子混合物的分子相互作用之间的差异并鉴定在一种混合物中分子特异性的配体的方法。 该方法利用组合文库来比较两种混合物的分子相互作用，并消除了混合物和第一种混合物独有的那些相互作用，从而确定了目标混合物基本上独特的相互作用。 然后可以鉴定目标混合物中分子特异性的配体。 本发明还包括筛选组合文库以区分真阳性珠和假阳性珠并提供对靶分子特异性的配体的鉴定的方法。

    Method for screening combinatorial bead library, capturing cells from body fluids, and ligands for cancer cells
    5.
    发明授权
    Method for screening combinatorial bead library, capturing cells from body fluids, and ligands for cancer cells 失效

    公开(公告)号：US06670142B2

    公开(公告)日：2003-12-30

    申请号：US10032678

    申请日：2001-10-26

    申请人： Derick H. Lau ,  Kit S. Lam

    发明人： Derick H. Lau ,  Kit S. Lam

    IPC分类号： G01N33574

    CPC分类号： C07K7/06 ,  G01N33/5011 ,  G01N33/54313

    摘要： The invention includes a cell-growth-on-bead assay for screening a one-bead-one-compound combinatorial bead library to identify synthetic ligands for cell attachment and growth or proliferation of epithelial cells. Cells are incubated with a compound bead library for 24 to 72-hours, allowing them to attach and grow on the beads. Those beads with cells growing are removed, and the ligand on the bead is identified. Also provided are ligands specific for epithelial cancer cells. The invention also includes a method of capturing epithelial cells from body fluids. In this method, beads are prepared with a known ligand specific for a particular type of cell and incubated for 24 to 72 hours with a sample of the body fluid being tested. Those cells attached to the beads are removed and identified.

    REVERSIBLY CROSSLINKED MICELLE SYSTEMS
    8.
    发明申请
    REVERSIBLY CROSSLINKED MICELLE SYSTEMS 审中-公开
    可反复交流的MICELLE系统

    公开(公告)号：US20150045419A1

    公开(公告)日：2015-02-12

    申请号：US14117570

    申请日：2012-05-14

    申请人： Kit S. Lam ,  Yuanpei Li

    发明人： Kit S. Lam ,  Yuanpei Li

    IPC分类号： C08G65/334 ,  A61K31/337 ,  A61K47/48 ,  A61K9/107

    CPC分类号： C08G65/3348 ,  A61K9/1075 ,  A61K9/1271 ,  A61K31/337 ,  A61K45/06 ,  A61K47/28 ,  A61K47/60 ,  C08G65/329 ,  C08G83/004 ,  C08L71/02 ,  Y10T428/2982

    摘要： The present invention provides amphiphilic telodendrimers that aggregate to form nanocarriers characterized by a hydrophobic core and a hydrophilic exterior. The nanocarrier core may include amphiphilic functionality such as cholic acid or cholic acid derivatives, and the exterior may include branched or linear poly(ethylene glycol) segments. Nanocarrier cargo such as hydrophobic drugs and other materials may be sequester in the core via non-covalent means or may be covalently bound to the telodendrimer building blocks. Telodendrimer structure may be tailored to alter loading properties, interactions with materials such as biological membranes, and other characteristics.

    摘要翻译： 本发明提供了聚合形成以疏水核心和亲水外部为特征的纳米载体的两亲性的前体衍生物。 纳米载体核可以包括两亲官能团，例如胆酸或胆酸衍生物，并且外部可以包括支链或直链的聚（乙二醇）链段。 纳米载体如疏水性药物和其他材料可以通过非共价方式螯合在核心中，或者可以共价结合到四聚体上。 Teendendrimer结构可以被定制以改变负载特性，与诸如生物膜的材料的相互作用以及其它特征。

    Heterocyclic ligands for integrin imaging and therapy
    10.
    发明授权
    Heterocyclic ligands for integrin imaging and therapy 有权
    用于整合素成像和治疗的杂环配体

    公开(公告)号：US08486370B2

    公开(公告)日：2013-07-16

    申请号：US12440219

    申请日：2007-09-07

    申请人： Richard D. Carpenter ,  Mirela Andrei ,  Ruiwu Liu ,  Kit S. Lam ,  Mark J. Kurth

    发明人： Richard D. Carpenter ,  Mirela Andrei ,  Ruiwu Liu ,  Kit S. Lam ,  Mark J. Kurth

    IPC分类号： A61K51/00

    CPC分类号： A61K51/0459 ,  A61K9/0014 ,  A61K9/0019 ,  A61K51/0453 ,  A61K51/0455 ,  Y02A50/401 ,  Y02A50/475

    摘要： The present invention provides α4β1 integrin ligands that display high binding affinity, specificity, and stability. The ligands comprise a peptide having n independently selected amino acids, wherein at least one amino acid is an unnatural amino acid or a D-amino acid, and wherein n is an integer of from 3 to 20. Methods are provided for administering the ligands for treating cancer, inflammatory diseases, and autoimmune diseases. Also provided are methods for administering the ligands for imaging a tumor, organ, or tissue in a subject.

    摘要翻译： 本发明提供显示高结合亲和力，特异性和稳定性的α4β1整联蛋白配体。 配体包含具有n个独立选择的氨基酸的肽，其中至少一个氨基酸是非天然氨基酸或D-氨基酸，并且其中n是3-20的整数。提供了用于给予 治疗癌症，炎性疾病和自身免疫性疾病。 还提供了施用用于成像受试者的肿瘤，器官或组织的配体的方法。